Neurocrine Biosciences, Inc. (NBIX) Social Stream



Neurocrine Biosciences, Inc. (NBIX): $102.27

0.48 (+0.47%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Featured Post From StockTwits About NBIX

$ATNF (1 of 6) Prof Lawrence Steinman Co-Founder & Co- Chairman •Discovered role of integrins, led to Natalizumab, highly effective treatment for MS & IBD•Tysabri sold to Biogen in 2017 for $3.25 BILLION Member of National Academy of Sciences, 4 International awards for Biomedical Innovation including Charcot Prize; founder of Centocor He currently is the George A. Zimmermann Endowed Chair in Neurology department at Stanford University. His lab at Stanford University is dedicated to understanding pathogenesis of autoimmune diseases,particularly multiple sclerosis. Has overseen success in the pharmaceuticals industry; & was on the board of Centocor, sold to JNJ for $4.9 BILLION , & Founder of Neurocrine Biosciences $NBIX NASDAQ company with an approximate $10 BILLION market cap.He served on the Board of Centocor & currently serves as advisor to Atreca. He received a B.A. from Dartmouth College & M.D. from Harvard Medical School, and is a Member of the National Academy of Sciences, USA
MDInvestments, published June 7, 2021

What Else are NBIX Traders Talking About?


Other tickers frequently mentioned alongside NBIX is ATNF.

Other Notable StockTweets About NBIX


$ATNF (1 of 6) Prof Lawrence Steinman Co-Founder & Co- Chairman •Discovered role of integrins, led to Natalizumab, highly effective treatment for MS & IBD•Tysabri sold to Biogen in 2017 for $3.25 BILLION Member of National Academy of Sciences, 4 International awards for Biomedical Innovation including Charcot Prize; founder of Centocor He currently is the George A. Zimmermann Endowed Chair in Neurology department at Stanford University. His lab at Stanford University is dedicated to understanding pathogenesis of autoimmune diseases,particularly multiple sclerosis. Has overseen success in the pharmaceuticals industry; & was on the board of Centocor, sold to JNJ for $4.9 BILLION , & Founder of Neurocrine Biosciences $NBIX NASDAQ company with an approximate $10 BILLION market cap.He served on the Board of Centocor & currently serves as advisor to Atreca. He received a B.A. from Dartmouth College & M.D. from Harvard Medical School, and is a Member of the National Academy of Sciences, USA

MDInvestments, published June 5, 2021

$ATNF (1 of 6) Prof Lawrence Steinman Co-Founder & Co- Chairman •Discovered role of integrins, led to Natalizumab, highly effective treatment for MS & IBD•Tysabri sold to Biogen in 2017 for $3.25 BILLION Member of National Academy of Sciences, 4 International awards for Biomedical Innovation including Charcot Prize; founder of Centocor He currently is the George A. Zimmermann Endowed Chair in Neurology department at Stanford University. His lab at Stanford University is dedicated to understanding pathogenesis of autoimmune diseases,particularly multiple sclerosis. Has overseen success in the pharmaceuticals industry; & was on the board of Centocor, sold to JNJ for $4.9 BILLION , & Founder of Neurocrine Biosciences $NBIX NASDAQ company with an approximate $10 BILLION market cap.He served on the Board of Centocor & currently serves as advisor to Atreca. He received a B.A. from Dartmouth College & M.D. from Harvard Medical School, and is a Member of the National Academy of Sciences, USA

MDInvestments, published May 22, 2021

Loading social stream, please wait...


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!




Page generated in 0.5857 seconds.